A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors,

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors,

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Pilaralisib (Primary) ; Tesevatinib (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 19 Aug 2015 Status changed from suspended to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 20 Oct 2008 Status changed from recruiting to suspended, based on infrormation from ClinicalTrials.gov.
    • 14 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top